Phaseline

Targets › BCL11A

BCL11A (BCL11 transcription factor A): drug programs, companies and trials

4 programs from 4 companies in 8 trials: 5 Phase 1, 3 Phase 3; Hematology; next expected readout Jun 2027.

Transcription factor. Associated with the BAF SWI/SNF chromatin remodeling complex. (UniProt, Q9H165)

Open in Phaseline: the race on BCL11A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vertex PharmaceuticalsExagamglogene Autotemcel (CTX001)
B-cell lymphoma/leukemia 11A gene editing negative modulator
BCL11APhase 3Sickle Cell Disease; Beta-ThalassemiaJun 2027
Daniel Bauerautologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer t
BCL11A enhancer targeting CRISPR/Cas9 gene editing
BCL11APhase 1Sickle Cell DiseaseDec 2028
St. Jude Children's Research HospitalGene-modified CD34+ cells
CRISPR/Cas9-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) designed to incre
BCL11APhase 1Sickle Cell DiseaseDec 2029
Editas MedicineEDIT-301 (renizgamglogene autogedtemcel, reni-cel)
ex vivo base editing of hematopoietic stem cells targeting BCL11A to increase fetal hemogl
BCL11APhase 1Sickle Cell Disease; Transfusion Dependent Beta Thalassemia–

Conditions

Sickle Cell Disease (5) Beta-Thalassemia (2) Transfusion Dependent Beta Thalassemia (1)

Modalities

other (2), protein or peptide (1), mixed (1)

Companies

Daniel Bauer (1) Vertex Pharmaceuticals (1) Editas Medicine (1) St. Jude Children's Research Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.